Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 10 years, with Q4 2025 value amounting to $13.9 million.

  • Ocular Therapeutix's Other Non-Current Liabilities rose 496.0% to $13.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.9 million, marking a year-over-year increase of 496.0%. This contributed to the annual value of $13.9 million for FY2025, which is 496.0% up from last year.
  • Ocular Therapeutix's Other Non-Current Liabilities amounted to $13.9 million in Q4 2025, which was up 496.0% from $15.0 million recorded in Q3 2025.
  • Ocular Therapeutix's Other Non-Current Liabilities' 5-year high stood at $73.3 million during Q1 2021, with a 5-year trough of $6.4 million in Q4 2022.
  • Its 5-year average for Other Non-Current Liabilities is $21.8 million, with a median of $14.2 million in 2024.
  • Per our database at Business Quant, Ocular Therapeutix's Other Non-Current Liabilities plummeted by 8253.62% in 2022 and then skyrocketed by 37216.19% in 2023.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Other Non-Current Liabilities stood at $20.2 million in 2021, then crashed by 68.55% to $6.4 million in 2022, then soared by 372.16% to $30.0 million in 2023, then crashed by 55.83% to $13.2 million in 2024, then increased by 4.96% to $13.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $13.9 million for Q4 2025, versus $15.0 million for Q3 2025 and $14.0 million for Q2 2025.